Essential Medicines for Africa

AfriPharma's comprehensive portfolio of WHO Essential Medicines serving 380 million people across the SADC region with quality sterile injectables and oral solid dosage forms manufactured to international standards.

12
Product Portfolio
21.6M
Annual Capacity
10
WHO EML Products
2027
First Launch
Filter by:
Phase 1a • Q3 2027

ParaFlow 1000

Paracetamol IV 1000mg/100mL

Indication: Adult pain and fever management. First-line treatment for moderate pain and pyrexia in hospital settings.

Presentation
100mL Glass Bottle
Strength
10mg/mL
Year 5 Target
2.5M units
Gross Margin
72%
WHO Essential Medicine Phase 1a Lead
Phase 1a • Q3 2027

ParaFlow 150

Paracetamol IV 150mg/10mL

Indication: Pediatric pain and fever management. Safe and effective analgesic for children.

Presentation
10mL Glass Vial
Strength
15mg/mL
Year 5 Target
1.5M units
Gross Margin
71%
WHO Essential Medicine Only WHO-PQ Pediatric IV
Phase 1a • Q3 2027

Metronidazole IV

500mg/100mL Infusion

Indication: Anaerobic bacterial infections, intra-abdominal sepsis, and protozoal infections.

Presentation
100mL Infusion Bottle
Strength
5mg/mL
Year 5 Target
3.6M units
Gross Margin
70%
WHO Essential Medicine High Volume
Phase 1a • Q3 2027 • NEW

TramaFlow

Tramadol IV 100mg/2mL

Indication: Moderate to moderately severe pain management. Post-operative, trauma, and cancer pain. WHO Step 2 analgesic.

Presentation
2mL Glass Ampoule
Strength
50mg/mL
Year 5 Target
2.4M units
Gross Margin
75%
NEW - Pain Management Prescription Only
Phase 1b • Q1 2028

Ciprofloxacin IV

200mg/100mL Infusion

Indication: Serious bacterial infections caused by gram-negative organisms. Broad-spectrum fluoroquinolone.

Presentation
100mL Infusion Bottle
Strength
2mg/mL
Year 5 Target
3.0M units
Gross Margin
73%
WHO Essential Medicine Phase 1b
Phase 1b • Q1 2028

Gentamicin

80mg/2mL Injectable

Indication: Serious gram-negative infections. Aminoglycoside antibiotic for sepsis and complex infections.

Presentation
2mL Ampoule
Strength
40mg/mL
Year 5 Target
4.8M units
Gross Margin
74%
WHO Essential Medicine Highest Volume
Phase 1b • Q3 2028

Dextrose 5%

500mL IV Solution

Indication: Hydration, caloric supplementation, and vehicle for drug administration.

Presentation
500mL BFS Bag
Strength
50mg/mL (5% w/v)
Year 5 Target
2.4M units
Technology
Blow-Fill-Seal
WHO Essential Medicine BFS Technology
Phase 1b • Q3 2028

Normal Saline 0.9%

500mL IV Solution

Indication: Fluid replacement, hydration, and vehicle for drug administration.

Presentation
500mL BFS Bag
Strength
9mg/mL (0.9% w/v)
Year 5 Target
1.4M units
Technology
Blow-Fill-Seal
WHO Essential Medicine BFS Technology
Phase 1b/1c • 2028

Metronidazole

400mg Tablets

Indication: Anaerobic infections, protozoal infections, and bacterial vaginosis.

Presentation
10 Tablets/Blister
Strength
400mg
Year 5 Target
5M tablets
Gross Margin
70%
WHO Essential Medicine Oral Solid Dosage
Phase 1c • 2028

Atenolol

50mg Tablets

Indication: Hypertension and cardiovascular disease. Beta-blocker for chronic disease management.

Presentation
30 Tablets/Bottle
Strength
50mg
Year 5 Target
1M tablets
Focus
NCD Market
WHO Essential Medicine NCD Focus
Phase 1c • 2028

Metformin

500mg Tablets

Indication: Type 2 Diabetes management. First-line oral hypoglycemic agent.

Presentation
30 Tablets/Bottle
Strength
500mg
Year 5 Target
2M tablets
Focus
NCD Market
WHO Essential Medicine NCD Focus

Partner with AfriPharma

For procurement inquiries, distribution partnerships, or investment opportunities, contact our team to learn how we're building pharmaceutical sovereignty in Africa.